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Abstract

Title:

Etomidate and Corticosteroid Administration in the Critically Ill
Patient

Background:

A 68-year-old male patient undergoing an exploratory laparotomy
bowel resection had a recent hospitalization due to sepsis with gramnegative bacteria and diverticulitis of the large colon with perforation.
Critically ill patients often undergo surgical procedures and require
anesthesia. Etomidate is an induction agent used for general
anesthesia and it is most known for its stable hemodynamic profile.
Unfortunately, adrenal suppression by etomidate was found as an
adverse effect and this finding remarkably limits its use in critically
ill patients. Since the discovery of adrenal suppression, the use of
corticosteroids to treat this corresponding adrenal suppression has
raised the attention of many researchers and clinicians.

Purpose:

To evaluate and conclude current recommendation on etomidate use
in the critically ill patient and the use of supplemental corticosteroids
in preventing adrenal insufficiency caused by etomidate use.

Process:

A systematic search was conducted utilizing CINAHL and PubMed
for research articles that were published in the last 8 years that
pertained to etomidate and corticosteroid administration in the
critically ill patient. Information from the review of literature was
synthesized to develop evidence-based recommendations for
critically ill patients.

Results:

Further large, randomized controlled trials are needed to fully
determine whether or not administration of corticosteroids will
prevent the adrenal insufficiency caused by etomidate use and if
etomidate should be administered to the critically ill patient. The
most recent and majority of studies found in the literature review
indicate corticosteroid use will not prevent the adrenal insufficiency
caused by etomidate use and that all together anesthesia providers
should consider completely eradicating the use of etomidate in
critically ill individuals.

Implications:

Informed decision-making should be utilized on a case-by-case basis
in regards to etomidate and corticosteroid use in the critically ill. It is
essential for anesthesia providers to consider evidence-based
recommendations to prevent potential adrenal insufficiency and
increased mortality with etomidate use.

Keywords:

Etomidate, corticosteroid, adrenal suppression, critically ill patient
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Background

Etomidate is a unique induction agent used for general anesthesia and sedation. In
1965, Janssen Pharmaceuticals first introduced etomidate as an antifungal agent, but to
their surprise, significant hypnotic activity was noticed. After this revelation, it was
introduced into clinical practice in 1972 as a hypnotic agent (Forman, 2011). Etomidate is
most known for its hemodynamic stability properties, as it does not inhibit sympathetic
tone or myocardial function, like other induction agents. Its benign hemodynamic effect
is the main reason this drug became popular for use in critically ill patients. Etomidate
has been used in emergency departments, intensive care units, and as the induction
medication of choice for critically ill patients.
Unfortunately, adrenal cortical inhibition by etomidate was found as an adverse
effect and this finding remarkably limits its use as both an anesthetic and sedative agent.
Etomidate inhibits 11β-hydroxylase, which prevents cortisol synthesis. “The inhibition of
this enzyme prevents cortisol from responding to stress and triggers a state of adrenal
insufficiency” (Black, 2014, p.6). Adrenal suppression can last “6 to 8 hours after a
single-induction dose and more than 24 hours after an infusion” (Forman, 2011, p.697).
In several studies conducted, the existence of adrenal suppression after etomidate
administration showed increased mortality amongst intensive care unit (ICU) patients
receiving etomidate infusions for sedation. Due to these findings, long-term etomidate
infusions were ceased and no longer recommended. Etomidate’s “drug packet insert was
amended to state that etomidate use is approved for induction of general anesthesia and
anesthetic maintenance for short operative procedures only” (Forman, 2011, p.698).
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Since the discovery of adrenal suppression from etomidate administration, the use
of corticosteroids to treat this corresponding adrenal suppression has raised the attention
of many researchers and clinicians. In a large multicenter trial, named the CORTICUS
study, exposure to single-dose etomidate was a cofounding variable in evaluating the use
of supplemental corticosteroids in septic patients with and without adrenal insufficiency.
The results of this study “concluded that supplemental steroids after etomidate
administration did not improve the long-term outcome of septic shock patients with
adrenal insufficiency” (Forman, 2011, p. 698). Conversely, other studies have indicated
cortisol replacement therapy could reduce the mortality in critically ill patients receiving
etomidate. Due to the conflicting evidence and the growing incidence of critically ill
individuals, should anesthesia providers administer corticosteroid replacement therapy
after etomidate administration in the critically ill patient?
Case Report
A 68-year-old, 163 cm, 72.5 kg, male patient with a body mass index (BMI) of
27.4 kg/m2, presented with a diagnosis of right lower abdominal pain and was scheduled
for an exploratory laparotomy bowel resection. Significant medical history included
sepsis due to gram-negative bacteria, diverticulitis of the large colon with perforation,
respiratory failure, hypokalemia, and congestive heart failure (CHF). Surgical history
included repair of abdominal aortic aneurysm and placement of cardiac stents. Patient
had allergies to rosuvastatin, morphine, clopidogrel, simvastatin, and nuts. Home
medications consisted of acetylsalicylic acid, famotidine, and naproxen sodium. Preoperative vital signs consisted of a blood pressure of 100/65, heart rate of 110, respiratory
rate of 23, and oxygen saturations of 87%. Pre-operative laboratory data included sodium
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of 142, potassium of 2.6, glucose of 142, creatinine of 0.9, blood urea nitrogen (BUN) of
11, chloride of 110, calcium of 8.6, magnesium of 2.3, pH of 7.40, PaCO2 of 37, PaO2 of
50, bicarbonate (HCO3) of 27, hemoglobin of 12.5, hematocrit of 38.3, platelets of 146,
white blood count (WBC) of 9.3, partial thromboplastin time (PTT) of 26.6, protime (PT)
of 14.9, and international normalized ration (INR) of 1.4. Mallampati classification was
assessed as a 3 preoperatively with an ASA classification of 4E.
The plan was to perform general anesthesia with a rapid sequence induction (RSI)
with placement of an endotracheal tube (ETT). Preoperatively the patient was given 1 mg
midazolam in the pre-operative holding room and continued on bipap therapy with
oxygen saturations of 90%. In the operating room, standard noninvasive monitors were
applied. Denitrogenation was accomplished with bipap therapy at 100% FiO2 and the
patient was induced intravenously (IV) with 50 mg lidocaine, 50 mcg fentanyl, 5 mg
rocuronium, 150 mg propofol, and 140 mg succinylcholine prior to placing an 8.0 ETT in
1 attempt with a Mac 3 blade. A grade 1 view was visualized and ETT placement was
verified by end-tidal carbon dioxide, bilateral breath sounds, condensation within the
tube, and bilateral chest rise. The tube was secured, eyes taped, and anesthetic maintained
with desflurane 6.8% with a mixture of 1.0 L/min of oxygen and 1.0 L/min of air.
Mechanical ventilation was applied with volume control (VC) mode, tidal volume of 700
mL, rate of 12/min, and positive end- expiratory pressure (PEEP) of 8 cm/H2O. An
arterial line was placed and medication administration was given through a central
catheter placed prior in the intensive care unit.
Following induction, the patient was placed in the supine position and
positioning concerns were verified with extremities padded. The patient continued to
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receive 3.375 g of scheduled zosyn prior to incision. The maintenance phase consisted of
fentanyl, rocuronium, potassium chloride, albumin, and a phenylephrine infusion. A total
of 2.8 liters of crystalloid solution was given intra-operatively, blood loss was estimated
at 175 mL, and urine output was 250 mL. Post-operative nausea and vomiting
prophylaxis was performed with 4 mg ondansetron and 8 mg dexamethasone. Due to
decreased oxygen saturations and inadequate arterial blood gases, the patient was left
sedated and intubated following the procedure. The patient was transferred to the surgical
critical care unit (SCCU) in stable condition. The duration of the procedure was
approximately 2.5 hours.
The patient remained in the SCCU where he remained sedated and intubated 4
days post-operatively due to hypoxic respiratory failure and acute exacerbation of CHF.
After the patient was extubated and in stable condition, he was transferred to the medical
floor where he remained for 4 additional days post-operatively. The patient was then
discharged home on postoperative day 8.
Discussion
As a result of etomidate’s hemodynamic tolerance, it is a first-line anesthetic
agent used to facilitate endotracheal intubation in hemodynamically unstable patients and
has emerged as an agent of choice for critically ill patients. “However, single-dose
etomidate has been found to block cortisol synthesis by specifically inhibiting the activity
of 11-β-hydroxylase, which is responsible for the conversion of 11-β-deoxycortisol into
cortisol in the adrenal gland” (Payen, et al., 2012, p. 29). This enzyme inhibition results
in primary adrenal insufficiency with effects lasting up to 48 hours post-administration
(Payen, et al., 2012). “Such adrenal insufficiency is associated with higher rates of

ETOMIDATE ADMINISTRATION
mortality and morbidity in critically ill individuals and raises concerns over the potential
for etomidate to worsen patient outcomes” (Payen, et al., 2012, p. 29). However, due to
etomidate’s hemodynamic stability properties, it raises the question of whether or not to
eliminate the use of etomidate all together or to add concomitant administration of
corticosteroids to prevent acute adrenal insufficiency.
Etomidate Administration
Etomidate is a common IV induction agent used in general anesthesia and in the
past has been used as a sedative in the ICU. It is a “carboxylated imidazole derivative that
was synthesized in 1965 and introduced to European anesthesia practice in 1972”
(Nagelhout & Plaus, 2014, p. 110). Etomidate consists of two isomers, but only the R(+)
isomer demonstrations hypnotic characteristics. It is supplied as a “2mg/mL preparation
with each milliliter containing 35% propylene glycol as a solvent and has a pH of 8.1 and
a pKa of 4.2” (Nagelhout & Plaus, 2014, p. 110). The IV induction dose of etomidate for
general anesthesia is 0.2-0.3 mg/kg. The drugs hallmark advantage over other induction
medications is that it promotes cardiovascular stability, which is the main reason it is
often the drug of choice in certain patient populations.
Pharmacokinetics
The mechanism of action of etomidate involves depression of the reticular
activating system and inhibition of GABA. “Etomidate’s R(+) isomer binds to a subunit
of the GABAA receptor, which increases the receptor’s affinity for the inhibitory
neurotransmitter, GABA” (Butterworth, Mackey, & Wasnick, 2013, p. 184). After IV
injection, it has a peak onset time of 1 minute. “Shortly after administration, the brain
concentration rises rapidly because of the drug’s lipid solubility and over the next several
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minutes, extensive redistribution to other organs and tissues occurs and the patient
regains consciousness” (Nagelhout & Plaus, 2014, p. 111). Etomidate is rapidly
metabolized in the liver by hepatic enzymes and plasma esterases via hydrolysis to form
inactive metabolites and has an elimination half-life of 2 to 5 hours (Black, 2014).
“Approximately 10% of the administered dose can be recovered in bile, 13% be
recovered in feces, and the remainder of the metabolites are eliminated by the kidney”
(Nagelhout & Plaus, 2014, p. 111). The rapid redistribution of etomidate accounts for its
extremely short duration of action.
Pharmacodynamics
Central nervous system (CNS) effects of etomidate include decreased cerebral
blood flow, cerebral metabolic rate of oxygen consumption and intracranial pressure, and
maintained cerebral perfusion pressure (Forman, 2011). A negative CNS characteristic of
etomidate is its excitatory phenomenon of tremors, known as myoclonia (Stoelting &
Hillier, 2006). The myoclonia is known to be so severe that it can resemble seizures.
“The origin of these muscle movements is thought to be related to uneven drug
distribution into the brainstem or deep cerebral structures and not to CNS stimulation”
(Nagelhout & Plaus, 2014, p. 111). Pretreatment with small doses of etomidate,
dexmedetomidine, midazolam, rocuronium, and lidocaine are all effective in reducing
myoclonia.
The primary advantage of etomidate is the hemodynamic stability it produces
upon induction. “Minimal changes in heart rate, blood pressure, central venous pressure,
and intrapulmonary shunting have been demonstrated after administration” (Nagelhout &
Plaus, 2014, p. 111). A minor decrease in blood pressure is theorized to be due to
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decreases in systemic vascular resistance. “The hemodynamic stability seen with
etomidate has been attributed to a unique lack of depression of sympathetic nervous
system and baroreceptor function” (Nagelhout & Plaus, 2014, p. 111). “Myocardial
oxygen supply and demand are kept constant by a balance of decreased myocardial blood
flow and decreased oxygen consumption” (Nagelhout & Plaus, 2014, p. 111). No
significant cardiac dysrhythmias are connected with its use.
Etomidate affects the respiratory system in a dose-dependent manner. Minute
volume decreases while respiratory rate increases. “The ventilatory response to carbon
dioxide is decreased and administration may cause brief periods of apnea following
induction” (Nagelhout & Plaus, 2014, p.111). “Etomidate produces minimal effect on
bronchial tone and does not cause histamine release” (Nagelhout & Plaus, 2014, p.111).
Adrenal Suppression
During the 1980’s, etomidate began to receive much attention regarding the
adrenal cortical inhibition it produced. Since this time, etomidate has been widely studied
for both its beneficial and detrimental effects. The adrenal suppression it creates
significantly limits its clinical use. Researches have found an increased mortality rate in
critically ill patients who received etomidate infusions (Forman, 2011). “This
phenomenon was attributed to adrenocortical hypofunction, demonstrated by decreased
levels of plasma cortisol” (Nagelhout & Plaus, 2014, p. 112). “Multiple studies have
shown adrenal hormone levels to be decreased for up to 8 to 24 hours after a singleinduction dose or more than 24 hours with an infusion” (Stoelting & Hillier, 2006, p.
166). These effects are caused by a reversible dose-dependent inhibition of adrenal
steroidgenesis. The enzymes inhibited are the cytochrome P-450-dependent
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mitochondrial enzymes and 11-β-hydroxylase (Nagelhout & Plaus, 2014). This inhibition
results in an increase in cortisol precursors but a decrease in cortisol, aldosterone, and
corticosterone levels (Forman, 2011). This enzyme inhibition results in decreased
ascorbic acid synthesis, which is necessary for steroid production” (Nagelhout & Plaus,
2014, p. 112).
Side-Effects/Contraindications
Etomidate is contraindicated in patients with a known sensitivity, adrenal
suppression, and acute porphyrias (Forman, 2011). It is associated with no analgesic
properties. Common side effects include pain on injection, thrombophlebitis, myoclonia,
nausea and vomiting, and most noting adrenocortical suppression (Forman, 2011).
Hypothalamic-Pituitary-Adrenal (HPA) System
The HPA axis is organized into three distinct regions: hypothalamus, pituitary
gland, and adrenal glands. “Specifically, the paraventricular nucleus is the hypothalamic
region that uses corticotrophin-releasing hormone (CRH) to stimulate the pituitary”
(Smith & Vale, 2006, p.385). Upon stimulation, the anterior pituitary releases
adrenocorticotrophin hormone (ACTH), which is transported in the general circulation to
the adrenal cortex of the adrenal glands. “The adrenal glands rapidly synthesize and
release cortisol and other hormones into the blood where it participates in the response to
stress and maintenance of homeostasis throughout the body” (Smith & Vale, 2006,
p.386). The adrenal glands are the effector organ of the HPA axis and its actions are
essential to maintain homeostasis (Smith & Vale, 2006).
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Adrenal Cortex & Corticosteroids
The adrenal glands are located at the superior facet of each kidney and consist of
the adrenal cortex and medulla. The adrenal medulla encompasses the central 20% of the
adrenal gland and secretes the hormones epinephrine and norepinephrine. The adrenal
cortex comprises the outer part of the adrenal gland and secretes three main types of
hormones: mineralocorticoids, glucocorticoids, and androgenic hormones (Nagelhout &
Plaus, 2014). The adrenal cortex is divided into three zones and includes the outermost
zona gomerulosa that secretes mineralcorticoids, the middle zona fasciculata that secretes
glucocorticoids, and the innermost zona reticularis that secretes androgens and estrogens
(Stoelting & Hillier, 2006).
The adrenal cortex produces more than 30 types of steroid hormones. “All
hormones secreted from the adrenal cortex have a steroidal structure and share a common
cholesterol backbone” (Nagelhout & Plaus, 2014, p.862). As a unit, these hormones are
termed corticosteroids. The two major classes of corticosteroids are mineralocorticoids
and glucocorticoids. “Mineralocorticoids influence the plasma concentrations of sodium
and potassium ions, whereas glucocorticoids influence carbohydrate, fat, and protein
metabolism, as well as exhibiting anti-inflammatory effects” (Stoelting & Hillier, 2006,
p. 809). Aldosterone is the primary mineralocorticoid, while cortisol is the main
glucocorticoid.
Corticosteroid: Mineralocorticoids
Mineralocorticoids, mainly aldosterone, play a vital role in regulating potassium
and sodium levels and total body fluid balance. “They are required for life and with a
total loss of mineralocorticoid secretion; death would ensue within days without
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treatment” (Nagelhout & Plaus, 2014, p. 863). Mineralocorticoids are produced in the
zona glomerulosa, the outermost layer of the adrenal cortex. An example of an
endogenous mineralocorticoid with no glucocorticoid properties is desoxycorticosterone.
An example of an exogenous mineralocorticoid is fludrocortisone, which contains minute
glucocorticoid properties. Mineralocorticoid inhibitors consist of spironolactone and
eplerenone (Stoelting & Hillier, 2006). Control of aldosterone secretion is independent of
ACTH control. “After secretion from the adrenal cortex, aldosterone circulates 60%
bound to serum proteins and has a relatively short half-life of about 20 minutes”
(Nagelhout & Plaus, 2014, p. 863). The four main stimulants of aldosterone release are
hyperkalemia, angiotensin II, hyponatremia, and ACTH (Nagelhout & Plaus, 2014).
Aldosterone secretion is regulated by the renin angiotensin mechanism and by blood
levels of potassium. Increased levels of aldosterone promote sodium retention by the
distal tubules of the kidney while increasing urinary losses of potassium” (Mattson Porth
& Matfin, 2009).
Corticosteroid: Glucocorticoids
Glucocorticoids are produced in the zona fasciculata and zona reticularis of the
adrenal gland. Cortisol, also known as hydrocortisone, is the main glucocorticoid and it
accounts for 95% of the glucocorticoids released from the adrenal cortex (Nagelhout &
Plaus, 2014). ACTH mainly regulates cortisol secretion and in turn, cortisol is the most
potent controller of ACTH. “Cortisol has a direct negative feedback effect on the
hypothalamus, inhibiting the release of CRH, and on the anterior lobe of the pituitary
gland, decreasing ACTH synthesis and release” (Nagelhout & Plaus, 2014, p. 863). When
cortisol concentration is high, the feedback system reduces ACTH production and vice

13!

ETOMIDATE ADMINISTRATION
versa. ACTH levels have significant diurnal variation and tend to reach their peak in the
early morning and decline as the day advances. “This variation appears to be due to
rhythmic activity in the CNS, which causes bursts of CRH secretion and, in turn, ACTH
secretion” (Mattson Porth & Matfin, 2009, p. 739). “The rhythm may be changed by
physical and psychological stresses, endogenous depression, manic-depressive psychosis,
and liver disease or other conditions that affect cortisol metabolism” (Mattson Porth &
Matfin, 2009, p. 739).
Under normal circumstances, cortisol production is 15 to 30 mg daily. Many
aspects of life can increase the amount of cortisol produced and can broadly be
categorized into physical and mental stress. “Stress, including surgery, typically raises
cortisol production levels to more than 100 mg/day” (Nagelhout & Plaus, 2014, p. 863).
The normal cortisol blood concentration averages 12 mcg/dL, and this may increase to 30
to 50 mcg/dL during and after major surgery” (Nagelhout & Plaus, 2014, p. 863).
After release from the adrenal cortex, cortisol circulates in blood in the form of
either free or bound cortisol. If bound, cortisol is attached to cortisol-binding globulin or
albumin. “Approximately 90% to 95% of cortisol is transported in the bound form and
6% is free” (Nagelhout & Plaus, 2014, p. 863). “Like other steroid hormones, cortisol
exerts its effects by binding to target cell nuclear receptors and alters gene transcription
and translation” (Nagelhout & Plaus, 2014, p. 863). Most of the metabolic effects of
cortisol are not instantaneous and may take several hours to fully foster. Cortisol is
inactivated mainly in the kidney and liver and excreted in the urine as 17hydroxycorticosteroids” (Nagelhout & Plaus, 2014, p. 863).
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Glucocorticoids execute a crucial function in response to stress and are critical
for survival. When created as part of the stress response, glucocorticoids assist in
regulating metabolic, immunologic, and anti-inflammatory functions. The metabolic
functions of cortisol involves stimulating glucose production by the liver, promoting
protein breakdown, and causing mobilization of fatty acids (Mattson Porth & Matfin,
2009). “As glucose production by the liver rises and peripheral glucose use falls, a
moderate resistance to insulin develops, and an increase in blood glucose develops”
(Mattson Porth & Matfin, 2009, p.739). Many of the immunologic and anti-inflammatory
actions accredited to cortisol result from the administration of pharmacologic levels of
the hormone. After administration, the increased amount of cortisol works by “blocking
inflammation at an early stage by decreasing capillary permeability and stabilizing the
lysosomal membranes so that inflammatory mediators are not released” (Mattson Porth &
Matfin, 2009, p.739). In addition, “cortisol suppresses the immune response by reducing
humoral and cell-mediated immunity and inhibiting prostaglandin synthesis, which may
account for its anti-inflammatory actions” (Mattson Porth & Matfin, 2009, p.739.
A characteristic of long-term pharmacologic preparations of glucocorticoid
therapy is the adrenal insufficiency produced from the withdrawal of the drugs. The
deficiency results from the suppression of the HPA system. “Chronic HPA suppression
causes atrophy of the adrenal gland, and the abrupt withdrawal of pharmacologic
preparations of glucocorticoids can cause acute adrenal insufficiency” (Mattson Porth &
Matfin, 2009, p.739). After chronic HPA suppression and abrupt withdrawal, recovery of
adrenal functioning can take up to 12 months or even more (Mattson Porth & Matfin,
2009). Therefore, a sufficient replacement should be provided to patients who lack
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adrenal function, whether it be pharmacological or pathophysiologic in nature, and who
are acutely ill or undergoing major surgeries.
A variety of synthetic glucocorticoids have been created for therapeutic use and
differ in both pharmacokinetics and pharmacodynamics. Glucocorticoid potency,
duration of effect, and the overlapping mineralocorticoid potency vary between each
drug. “Cortisol is the standard of comparison for glucocorticoid potency and
hydrocortisone is the name used for pharmaceutical preparations of cortisol” (Stoelting &
Hillier, 2006, p.810). Examples of glucocorticoids include: cortisol, cortisone,
prednisone, prednisolone, methylprednisolone, dexamethasone, betamethasone,
triamcinolone, and beclometasone (Stoelting & Hillier, 2006). In comparison,
hydrocortisone’s glucocorticoid and mineralocorticoid potency is equal and has a short
duration of action, while dexamethasone has only glucocorticoid properties with no
mineralocorticoid involvement and a long duration of action. For the sole fact
hydrocortisone has additional mineralocorticoid effects, while dexamethasone does not, it
is often the drug of choice when supplemental replacement is needed in individual cases
where high stress environments are encountered or long-term use has been identified.
The Critically Ill Patient
“Sepsis, severe sepsis, and septic shock are all inflammatory states resulting from
a systemic response to bacterial infection” (Maggio & Carvalho, 2015). Sepsis embodies
a gamut of disease ranging from systemic inflammatory response syndrome (SIRS) to
septic shock. SIRS is a collection of symptoms of systemic inflammation that may or
may not be the result of an infection. Manifestations of SIRS includes a “temperature
greater than 38 degrees Celsius, heart rate greater than 90 beats per minutes, respiratory
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rate greater than 20 breaths per minutes or PaCO2 less than 32 mmHg, and a WBC count
greater than 12,00 cells/ųL or less than 4,000 cells/ųL” (Maggio & Carvalho, 2015).
Sepsis is defined as greater than or equal to 2 SIRS criteria with known or suspected
infection and severe sepsis is sepsis with organ dysfunction (Maggio & Carvalho, 2015).
Lastly, septic shock is “sepsis with refractory hypotension and impaired organ perfusion
despite adequate fluid resuscitation” (Maggio & Carvalho, 2015).
“Most cases of septic shock are caused by hospital-acquired gram-negative bacilli
or gram-positive cocci and often occur in immunocompromised patients and patients with
chronic and debilitating diseases” (Maggio & Carvalho, 2015). Septic shock appears
more often in the populations of neonates, elderly, and childbearing women. Predisposing
factors include “diabetes mellitus, cirrhosis, leukopenia, prior treatment with antibiotics
or corticosteroids, and invasive devices such as endotracheal tubes, vascular or urinary
catheters, drainage tubes, and other foreign materials” (Maggio & Carvalho, 2015).
Common causative sites of infection include the lungs and the urinary, biliary, and
gastrointestinal tracts.
The pathophysiology of septic shock is not completely known or understood.
Researchers do know “an inflammatory stimulus triggers production of pro-inflammatory
mediators, which cause neutrophil–endothelial cell adhesion, activation of the clotting
cascade, and generation of microthrombi” (Maggio & Carvalho, 2015). Pro-inflammatory
mediators involved include tumor necrosis factors (TNF), interleukin-1 (IL-1),
leukotrienes, lipoxygenase, histamine, bradykinin, serotonin, and interleukin-2 (IL-2)
(Maggio & Carvalho, 2015). The aforementioned mediators are opposed by antiinflammatory mediators, such as interleukin-4 (IL-4) and interleukin-10 (IL-10), resulting
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in a negative feedback mechanism. Initially, warm shock occurs by evidence of arteries
and arterioles dilating, decreasing peripheral arterial resistance, and increasing cardiac
output (Maggio & Carvalho, 2015). During the increase in cardiac output, vasoactive
mediators cause blood flow to bypass capillary exchange vessels. As a result, poor
capillary flow from shunting, along with capillary obstruction by microthrombi,
decreases delivery of oxygen and impairs removal of carbon dioxide and waste products
(Maggio & Carvalho, 2015). Decreased perfusion then causes organ dysfunction to one
or more organs, including the kidneys, lungs, liver, brain, and heart. Coagulopathy may
also develop because of intravascular coagulation with consumption of major clotting
factors. Following the warm stage, cardiac output may decrease, blood pressure fall, and
typical symptoms of shock will appear.
Signs and symptoms of sepsis can initially be subtle and easily mistaken for
manifestations of other diseases. With sepsis, patients typically manifest with fever,
tachycardia, diaphoresis, and tachypnea, while often times blood pressure will remain
within normal limits (Maggio & Carvalho, 2015). As severe sepsis or septic shock begins
to develop, an early sign encountered may be confusion or a decreased level of
consciousness. In this state, blood pressure will be decreased, yet the skin will appear
unexpectedly warm initially. Later, extremities become cool and pale, with peripheral
cyanosis and mottling occurring. Organ dysfunction will ensue from the inadequate
perfusion and cause additional signs and symptoms specific to the organ involved.
Treatment includes restoring perfusion with intravenous fluids, vasopressors, oxygen
therapy, broad-spectrum antibiotics, source control, and other supportive measurements,
such as insulin and corticosteroids (Maggio & Carvalho, 2015).
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Etomidate & Corticosteroid Administration
Evidence has concluded etomidate is capable of causing acute adrenal
insufficiency and even a single-dose has been demonstrated to inhibit cortisol production
for up to 48 hours (Marik, 2012). The idea of corticosteroid supplementation after
etomidate use has been proposed to combat the adrenal insufficiency (Marik, 2012). A
randomized, controlled, double-blind study conducted in 2012 by Payen, et al. provided
some guidance to this discussion. “The authors’ research disclosed that a moderate-dose
of hydrocortisone, 200-300 mg/day, has been successfully proposed to overcome critical
illness-related adrenal insufficiency, particularly in septic patients responding poorly to
fluid resuscitation and vasopressor agents. The more rapid resolution of septic shock and
reduction of norepinephrine doses suggested the potential usefulness of moderate-dose
hydrocortisone in patients with vasopressor-dependent septic shock. However, the
effectiveness of moderate-dose hydrocortisone has never been prospectively tested during
the period of etomidate-related adrenal insufficiency. Therefore, this study sought to
investigate the effectiveness of moderate-dose hydrocortisone at decreasing the
proportion of vasopressor-dependent patients without septic shock after single-dose
etomidate” (Payen, et al., 2012, p.29).
Payen and colleagues study sought to investigate the effects of moderate-dose
hydrocortisone on hemodynamic status in critically ill patients throughout the period of
etomidate-related adrenal insufficiency. The study involved 97 critically ill patients to
receive a 42-hour continuous infusion of either hydrocortisone or a placebo after a single
intubating dose of etomidate. The authors excluded individuals who had known HPA axis
dysfunction and prior use of corticosteroids. Based on a corticotropin-stimulation test and
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measurement of 11-β-deoxycortisol concentration, 87% of patients fulfilled the
diagnostic criteria for etomidate-related adrenal insufficiency 6 hours after the dose of
etomidate (Payen, et al., 2012).
Payen and associates study concluded critically ill patients without septic shock
did not benefit from hydrocortisone administration to overcome etomidate-related
insufficiency and replacement doses of hydrocortisone are not required after a single dose
of etomidate. There were no changes associated with the use of moderate-dose
hydrocortisone, nor did it affect the ICU length of stay, the number of days on the
ventilator, or the 28-day mortality. Following the release of this study, Dr. Marik and Dr.
Dmello wrote two separate editorials, both agreeing with Payen and colleagues. Dr.
Marik wrote there was no difference found between the group that had received the
hydrocortisone and the placebo group” (Marik, 2012). They both advised against the use
of routine steroid supplementation after etomidate use in critically ill patients, as it does
not appear to improve mortality. Dr. Marik and Dr. Dmello purposed these conclusions
might even go further and additionally apply to patients with severe sepsis and septic
shock.
An observational study conducted in 2012 by Jung, et al. focused on septic shock
patients treated with hydrocortisone after etomidate administration. “The aim of this
study was to compare septic shock patients who received etomidate versus another
induction drug both for short-term safety and long-term outcomes” (Jung, et al., 2012,
p.1). The study consisted of 60 patients in the etomidate cohort and 42 patients in the
non-etomidate cohort. Critical illness-related corticosteroid insufficiency was 79% in the
etomidate cohort and 52% in the non-etomidate cohort. This study suggested “septic
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shock patients treated with hydrocortisone after etomidate use was not associated with a
decrease of life-threatening complications following intubation in comparison with other
hypnotics” (Jung, et al., 2012, p. 7). It also concluded that etomidate was associated with
a “longer period of shock and a higher cumulative dose of hydrocortisone than patients
intubated with another hypnotic” (Jung, et al, 2012, p.8).
“The Corticosteroid Therapy of Septic Shock (CORTICUS) study was a
prospective, multicentered, randomized, double-blind, placebo-controlled trial” (Toma,
Stone, Green, & Gray, 2011, p.273). Patients were recruited from 52 ICU’s in nine
countries from March 2002 to November 2005. “Patients were 18 years of age or older
with clinical evidence of infection, evidence of systemic response to infection, and
hypoperfusion or organ dysfunction attributable to sepsis” (Toma, et al., 2011, p.273).
Five hundred patients were randomized to receive either hydrocortisone or placebo and
all patients were to undergo a corticotropin stimulation test prior to initiation of therapy.
“The results of this study concluded supplementation of hydrocortisone to compensate
for the potential negative effects of etomidate on outcomes does not seem to work” (Van
Dan Heuvel, et al., 2013, p.407). “Hydorcortisone administration had no effect on
outcome in these patients, and therefore the use of hydrocortisone to treat etomidate
related adrenal insufficiency should be reevaluated” (Cuthbertson, et al., 2009, p. 1874).
The article also included tips from other current evidence and indicated patients with
septic shock that receive corticosteroids may benefit from a faster resolution of
hypotension if corticosteroids are administered within the first 8 hours of the diagnosis of
sepsis. Although, this potential benefit has to be weighed against the possible increase in
superinfection and recurrent shock (Toma, et al., 2011).
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Therefore, informed decision-making should be utilized on a case-by-case basis
when using etomidate in critically ill patients with severe sepsis or septic shock, and
perhaps corticosteroids should be reserved for refractory shock, independent of etomidate
use. It is purposed that the “efficacy of corticosteroids may be related to enhancing the
hemodynamic response to norepinephrine rather than the mitigation of etomidate-related
11-β-hydroxylase inhibition” (Dmello, 2012, p.2004). Due to the lack of abundant studies
indicating a potential benefit of corticosteroid use, it is apparent that future randomized
controlled studies need to be conducted to confirm these findings.
Etomidate & Critically Ill Patients
The dispute over etomidate use in critically ill patients has been a topic of debate
for years. “As a result of its excellent hemodynamic tolerance, etomidate is a first-line
anesthetic agent used to facilitate endotracheal intubation in hemodynamically unstable
patients and has emerged as an agent of choice for RSI in critically ill patients.” (Payen,
et al., 2012, p.29). However, single dose etomidate blocks cortisol synthesis and causes
primary adrenal insufficiency with effects lasting up to 48 hours post-administration
(Payen, et al., 2012). “Such adrenal insufficiency is associated with higher rates of
mortality and morbidity in the ICU, raising concerns over the potential for etomidate to
worsen patient outcome as was shown in patients with septic shock or with trauma”
(Payen, et al., 2012, p. 29). Etomidate is recognized to cause adrenal suppression in both
elective surgical patients and more profoundly in the critically ill.
In critically ill patients, induction with etomidate is hypothesized to be associated
with an increased risk of mortality. “Previous randomized studies suggest a modest trend
toward an increased risk of death among etomidate recipients; however, this relationship
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has not been measured with great statistical precision” (Sunshine, et al., 2013, p. 639). A
study conducted in 2013 by Sunshine, et al. aimed to test whether etomidate is associated
with an increased risk of hospital mortality and other clinical outcomes in critically ill
patients. The study was a “retrospective cohort study conducted 2001 to 2005 and
consisted of 824 subjects requiring mechanical ventilation, who underwent adrenal
function testing in the ICU’s of 2 academic medical centers” (Sunshine, et al., 2013, p.
639). The primary outcome was in-hospital mortality, comparing subjects given
etomidate to those given an alternative induction agent. The results of the study
concluded the “relative risk of death among the etomidate recipients was higher than that
of subjects given an alternative agent” (Sunshine, et al., 2013, p.645). The authors of this
study also added these findings are similar to the collective results of smaller randomized
trials conducted to date.
In a 2013 review, Van Den Heuvel and collegues sought out to evaluate the most
recent publications in the long-lived debate over the use of etomidate in critically ill
septic patients. In the review, the authors discussed three recent meta-analyses of
randomized controlled trials and observational studies. In the first meta-analysis, “five
studies were identified that assessed mortality, in which a total of 865 subjects were
included” (Van Dan Heuvel, et al., 2013, p.407). This analysis indicated that subjects
who received etomidate were more likely to die. In the same meta-anaylsis, “seven
studies addressed the development of adrenal suppression associated with the
administration of etomidate and 1303 subjects were included” (Van Dan Heuvel, et al.,
2013, p.407). Etomidate administration increased the likelihood of developing adrenal
insufficiency. A second recent meta-analysis came to the same conclusion. Lastly, in the
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largest meta-analysis including critically ill patients with and without sepsis, 21 articles
were evaluated. “The meta-analysis compared etomidate versus non-etomidate anesthesia
and demonstrated an increased risk ratio for adrenal insufficiency and an increased risk
ratio for mortality” (Van Dan Heuvel, et al., 2013, p.407). Therefore, all three metaanalyses concluded findings of adrenal insufficiency and an increase in mortality after
use of etomidate (Van Den Heuvel, et al., 2013).
Dr. Brian Fengler wrote an article in the American Journal of Emergency
Medicine discussing previous studies conducted in the emergency department (ED). His
summarized research indicated that healthy, elective surgical patients who received
etomidate, only showed a transient and not clinically significant adrenal suppression
(Fengler, 2007). However, Dr. Fengler found “retrospective studies in the pediatric and
adult intensive care literature that showed an association between a single induction dose
of etomidate in critically ill septic patients and sustained suppression of the adrenal axis
with an increase in mortality” (Fengler, 2007, p. 229). Along with Dr. Fengler’s findings
and the previously mentioned CORTICUS study, both concluded patients who received
etomidate had an increased risk of mortality compared to those with an alternative
induction agent. In addition, a letter to the editor relating to the CORTICUS study by Dr.
Paul Dean also agreed. Dr. Dean concluded “etomidate no longer has a role as the
induction agent of choice in patients with septic shock in the anesthetic room or intensive
care unit” (Dean, 2012).
In the previous studies described, it is apparent there is a lack of cause and effect
when attempting to specifically link etomidate and increased mortality. There are many
other factors in the critically ill patient that could also contribute to increased mortality.
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Further studies are needed to address this fact and determine if the adrenal insufficiency
leads to increased mortality itself or if it more multifactorial in nature.
In opposition to the above-mentioned conclusions, two studies were found to have
the opposite conclusion. The first study was a retrospective 18-month cohort study
performed in a multidisciplinary ICU of an academic tertiary care institution. Patients
with severe sepsis and septic shock who were intubated and mechanically ventilated were
identified and grouped as having received single-dose etomidate during intubation or not.
Hospital mortality, ICU length of stay, number of ventilator day, vasopressor use, and
demographic and clinical variables were recorded (Dmello, Taylor, O’Brien, &
Matuschak, 2010). Two hundred twenty-four patients were identified and 113 received
etomidate. “The results of this study indicated single-dose etomidate used during RSI in
critically ill patients with severe sepsis and septic shock was not associated with
increased mortality, vasopressor use, ICU length of stay, or number of ventilator days”
(Dmello, et al., 2010, p. 1327). The second study conducted by Hohl et al. in 2009, was a
quantitative and qualitative systematic review of the literature. These individuals
reviewed 3,083 titles and only 20 met their inclusion criteria. There were many
limitations listed in this study. Hohl et al. concluded “etomidate suppresses adrenal
function transiently without demonstrating a significant effect on mortality” (Hohl, et al.,
2009, p.105).
Large, randomized controlled trials and studies specifically linking the cause and
effect of etomidate and mortality are needed to finalize the role of etomidate in critically
ill patients. Many studies advise against the use of etomidate in critically ill individuals
but the propounding data to support this is not all the way there yet. Many studies suggest
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practitioners to seek out alternative induction techniques for hemodynamically unstable
patients, including a high opioid and low dose propofol infusion or a combination of
ketamine and propofol in order to prevent post-induction hypotension (Black, 2014).
Conclusion
In conclusion, additional large, randomized controlled studies are needed to
provide a definite conclusion to the question of whether or not etomidate should be
administered to the critically ill patient and if administration of corticosteroids will
prevent adrenal insufficiency after etomidate use. The majority of recent research
indicates corticosteroid use will not prevent the adrenal insufficiency caused by
etomidate use and that all together anesthesia providers should consider completely
eradicating the use of etomidate in critically ill individuals. In the aforementioned case
study, etomidate or corticosteroid administration was not chosen for the critically ill
individual for these reasons. Furthermore, it is apparent the dilemma anesthesia personnel
face due to the complexity associated with the critically ill patient. However, without
definitive evidence supporting the use of etomidate in the critically ill or the use of
corticosteroid replacement following etomidate use, it would be prudent for the
anesthesia provider to consider using other safer alternatives.
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History%of%Etomidate%
• In%1965,%Janssen%Pharmaceu1cals%ﬁrst%
introduced%it%as%an%an1fungal%agent%%
• Presented%into%clinical%prac1ce%in%1972%as%a%
hypno1c%agent%%
• Most%known%for%its%stable%hemodynamic%
proper1es%%
• Drug%of%choice%for%cri1cally%ill%pa1ents%for%this%
sole%fact%

Etomidate%and%Cor1costeroid%
Administra1on%in%the%Cri1cally%Ill%
Pa1ent%
Julie%Honeyman,%SRNA%

Forman,%2011%

Etomidate%and%Adrenal%Suppression%

Review%of%Literature%

• Adrenal%suppression%was%discovered%as%an%
adverse%eﬀect%
• Inhibits%11βShydroxylase%
• Persists%6S8%hours%aUer%a%singleSinduc1on%dose%
and%more%than%24%hours%aUer%an%infusion%
• Administra1on%of%cor1costeroids%has%raised%
the%aWen1on%of%many%researchers%and%
clinicians%

• A%review%of%literature%was%conducted%using%the%
Harley%E.%French%Library%to%determine%current%
recommenda1ons%on%the%following%ques1on:%
!Should%anesthesia%providers%administer%
cor1costeroid%replacement%therapy%aUer%
Etomidate%administra1on%and%should%
Etomidate%be%used%in%cri1cally%ill%pa1ents?%%%
%

%

%

Black,%2014;%Forman,%2011%

Case%Informa1on%
• Surgical%Procedure:%Exploratory%laparotomy/%
bowel%resec1on%%
• Age:%68%yearSold%
• Weight/Height/BMI:%75%kg,%163cm,%27.4kg/m2%
• Gender:%Male%
• Allergies:%Rosuvasta1n,%Morphine,%
Clopidogrel,%Simvasta1n,%and%nuts%
• ASA:%4E%

Preopera1ve%Evalua1on%
• Signiﬁcant%Medical%History:%Sepsis%due%to%gramS
nega1ve%bacteria,%diver1culi1s%of%large%colon%
with%perfora1on,%respiratory%failure,%
hypokalemia,%and%CHF%
• Surgical%History:%AAA%repair%and%cardiac%stents%
• Home%Medica1ons:%Acetylsalicylic%acid,%
Famo1dine,%and%Naproxen%Sodium%
• PreSop%VS:%BP%100/65,%HR%110,%RR%23,%SpO2%87%%
• Airway%Evalua1on:%M%III,%TM%distance%>3%FB,%
mouth%opening%>3%FB,%and%full%neck%ROM%
%
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Preopera1ve%Evalua1on%
•
•
•
•
•
•
•
•

Laboratory(Data:(
Na%142%mEq/L%
K(2.6(mEq/L(
Glucose%142%mg/dL%
Cl%110%mmol/L%
Ca%8.6%mg/dL%
Mg%2.3%mEq/L%
Crea1nine%0.9%mg/dL%
BUN%11%mg/dL%

%
•
•
•
•
•
•
•

pH%7.40%
pCO2%37%
pO2(50!!(
HCO3%27%
Hgb%12.5%g/dL%
Hct%38.3%%
Plts%146%

Intraopera1ve%Issues%
• Con1nued%tachycardia"%IV%Fluids%and%PRN%
fentanyl%
• Hypotension%encountered"%IV%Fluids%and%
phenylephrine%infusion%
• Decreased%SpO2"%100%%O2,%ABG’s%drawn,%and%
tenta1ve%plan%to%keep%pa1ent%intubated%at%the%
end%of%the%procedure%

Anesthe1c%Course%
• GETA(with(RSI:((Emergent(case)( • AddiMonal(MedicaMons:(
SMidazolam%1%mg%
SZosyn%3.375%g%
SDenitrogena1on%with%bipap%therapy% SFentanyl%
SFentanyl%50%mcg%
SRocuronium%
SLidocaine%50%mg%
SPotassium%Chloride%
SRocuronium%5%mg%
SAlbumin%
SPropofol(150(mg(
SPhenylephrine%infusion%
SSuccinylcholine%140%mg%
SOndansetron%4%mg%
S8.0%ETT%via%Mac%3%blade%
SDexamethasone%8%mg%
SDesﬂurane%6.0%%
SArterial%line%placed%
SCentral%line%present%

Postopera1ve%S%SCCU%
• Decreased%SpO2%and%inadequate%ABG’s%
• Transferred%to%SCCU%where%he%remained%intubated%4%
days%due%to%hypoxic%respiratory%failure%
• Transferred%to%medical%ﬂoor%for%4%addi1onal%days%
• Discharged%home%on%postSopera1ve%day%8%
%
• Case(Totals:(
SUrine%output:%250%mL%
SEBL:%175%mL%
SLR:%2.8%L%
SCase%dura1on:%2.5%hours%

Etomidate’s%MOA%

Etomidate%

• Involves%depression%of%the%re1cular%ac1va1ng%
system%and%inhibi1on%of%GABA%
• R(+)%isomer%binds%to%the%subunit%of%the%GABAA%
receptor,%which%increases%the%receptor’s%
aﬃnity%for%the%inhibitory%neurotransmiWer,%
GABA%
• FirstSline%anesthe1c%agent%in%hemodynamically%
unstable%pa1ents%%
• Agent%of%choice%for%cri1cally%ill%individuals%

• It%has%been%widely%studied%for%both%its%beneﬁcial%and%
detrimental%eﬀects%
• A%single%dose%has%been%found%to%block%cor1sol%
synthesis%by%speciﬁcally%inhibi1ng%the%ac1vity%of%11βS
hydroxylase%%
• Adrenal%insuﬃciency%has%been%documented%for%up%to%
48%hours%postSadministra1on%aUer%a%single%dose!%
• Increased%mortality%rate%in%cri1cally%ill%pa1ents%
receiving%infusions%%

Nagelhout%&%Plaus,%2014;%BuWerworth,%Mackey,%&%Wasnick,%2013%

Payen,%et%al,%2012;%Forman,%2011;%Nagelhout%&%Plaus,%2014

%
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Cor1costeroids%%
• Adrenal%cortex%secretes%three%main%types%of%hormones:%
mineralocor1coids,%glucocor1coids,%and%androgenic%
hormones%%
• All%hormones%produced%are%termed%cor1costeroids%
• Two%major%classes%are%mineralocor1coids%and%glucocor1coids%%
• Mineralocor1coids%inﬂuence%the%plasma%concentra1on%of%
sodium%and%potassium%ions%%
• Glucocor1coids%inﬂuence%carbohydrate,%fat,%and%protein%
metabolism,%as%well%as%exhibi1ng%an1Sinﬂammatory%eﬀects%
• Aldosterone%is%the%primary%mineralocor1coid%
• Cor1sol%is%the%main%glucocor1coid%
Nagelhout%&%Plaus,%2014;%Stoel1ng%&%Hillier,%2006%

Glucocor1coids%
• Execute%a%crucial%func1on%in%response%to%
stress%and%are%cri1cal%for%survival%%
• When%created%as%part%of%the%stress%response,%
they%assist%in%regula1ng%metabolic,%
immunologic,%and%an1Sinﬂammatory%func1ons%
• Cor1sol,%also%known%as%hydrocor1sone,%
accounts%for%95%%of%the%glucocor1coids%
released%from%the%adrenal%cortex%
Nagelhout%&%Plaus,%2014%

%

Glucocor1coids%

Etomidate%and%Cor1costeroid%
Administra1on%%

• Examples:%Cor1sol,%Cor1sone,%Prednisone,%Prednisolone,%
Methylprednisolone,%Dexamethasone,%Betamethasone,%
Triamcinolone,%and%Beclometasone%
• Potency,%dura1on%of%eﬀect,%and%the%overlapping%
mineralocor1coid%potency%vary%between%each%drug%
• Cor1sol%is%the%standard%of%comparison%and%
hydrocor1sone%is%the%name%used%for%pharmaceu1cal%
prepara1ons%of%cor1sol%%
• In%comparison,%hydrocor1sone’s%glucocor1coid%and%
mineralocor1coid%potency%is%equal%and%has%a%short%
dura1on%of%ac1on,%while%dexamethasone%has%only%
glucocor1coid%proper1es%with%no%mineralocor1coid%
involvement%and%a%long%dura1on%of%ac1on%

• The%idea%of%cor1costeroid%supplementa1on%aUer%
Etomidate%use%has%been%proposed%to%combat%the%adrenal%
insuﬃciency%produced%from%its%use%
• Payen%and%colleagues%study:%Concluded%cri1cally%ill%
pa1ents%without%sep1c%shock%do%not%beneﬁt%from%
Hydrocor1sone%administra1on%and%replacement%doses%
are%not%required%aUer%a%single%dose%of%Etomidate%
• Dr.%Marik%and%Dr.%Dmello:%Agreed%with%Payen%et%al.%and%
advised%against%the%use%of%rou1ne%steroid%
supplementa1on%
%

Stoel1ng%&%Hillier,%2006%

Payen,%et%al.,%2012;%Marik,%2012;%Dmello,%2012%%

Etomidate%and%Cor1costeroid%
Administra1on%%

Etomidate%and%Cri1cally%Ill%Pa1ents%

• Jung%and%associates%study:%Suggested%sep1c%
shock%pa1ents%treated%with%Hydroco1sone%
aUer%Etomidate%was%not%associated%with%a%
decrease%in%lifeSthreatening%complica1ons%in%
comparison%to%other%hypno1cs%
• CORTICUS%study:%Concluded%supplementa1on%
of%Hydrocor1sone%to%compensate%for%the%
adrenal%insuﬃciency%caused%by%Etomidate%is%
ineﬀec1ve%

• The%dispute%over%Etomidate%use%in%cri1cally%ill%
pa1ents%has%been%a%topic%of%debate%for%years%
due%to%the%acute%adrenal%insuﬃciency%
• Such%adrenal%insuﬃciency%is%hypothesized%to%
be%associated%with%higher%rates%of%mortality%
• Sunshine%and%colleagues%study:%Concluded%the%
rela1ve%risk%of%death%among%the%Etomidate%
recipients%was%higher%than%that%of%subjects%
given%an%alterna1ve%agent%

Jung%et%al.,%2012;%Toma%et%al.,%2011;%Van%Dan%Heuvel%et%al.,%2013;%Cuthbertson%et%al.,%2009%%

Sunshine%et%al.,%2013%
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Etomidate%and%Cri1cally%Ill%Pa1ents%

Recommenda1ons%

• Van%Den%Heuvel%and%associates%review:%All%three%
metaSanalyses%concluded%ﬁndings%of%adrenal%
insuﬃciency%and%an%increase%in%mortality%
• Dr.%Brian%Fengler%review:%His%summarized%
research%indicated%an%associa1on%between%a%
single%induc1on%dose%of%Etomidate%in%cri1cally%ill%
sep1c%pa1ent%and%sustained%suppression%of%the%
adrenal%axis%with%an%increase%in%mortality%
• Dr.%Dean’s%leWer%to%the%editor:%Concluded%
Etomidate%no%longer%has%a%role%as%the%induc1on%
agent%of%choice%in%pa1ents%with%sep1c%shock%

• It%is%essen1al%for%anesthesia%providers%to%consider%
evidenceSbased%recommenda1ons%to%prevent%poten1al%
adrenal%insuﬃciency%and%increased%mortality%with%
Etomidate%use%
• Lack%of%abundant%studies%indica1ng%a%poten1al%beneﬁt%of%
cor1costeroids%use%
• Many%studies%advise%against%the%use%of%Etomidate%in%
cri1cally%ill%individuals%%
• Studies%speciﬁcally%linking%the%cause%and%eﬀect%of%
Etomidate%on%mortality%are%needed%%
• Several%studies%suggest%prac11oners%to%seek%out%
alterna1ve%induc1on%techniques%

Van%Dan%Heuvel,%et%al.,%2013;%Fengler,%2007;%Dean,%2012%%

%

Conclusion%
• Addi1onal%large,%randomized%controlled%studies%
are%needed%to%provide%a%deﬁnite%conclusion%%
• The%majority%of%recent%research%indicates%
cor1costeroids%will%not%aid%in%preven1ng%adrenal%
insuﬃciency%and%anesthesia%providers%should%
consider%completely%eradica1ng%the%use%of%
Etomidate%in%cri1cally%ill%individuals%
• In%the%aforemen1oned%case%study,%Etomidate%or%
cor1costeroids%were%not%used%for%these%reasons%
%
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